前列腺癌外照射联合高剂量率近距离治疗后的缺氧与血管生成生物标志物
该研究基于一项3期随机对照试验的前列腺穿刺活检样本,采用免疫组化检测HIF1α、GLUT1、OPN及CD-34标记的微血管密度,分析其与生化复发无生存和远处转移无生存的关系。结果显示OPN和GLUT1高表达预测更差BRFS,GLUT1高表达预测更差DMFS;在EBRT+HDR-BTb组中MVD和OPN高表达与BRFS改善相关而GLUT1低表达与BRFS改善相关。
要点
- OPN和GLUT1高表达与更差BRFS相关。
- GLUT1高表达与更差DMFS相关。
- EBRT+HDR-BTb组中MVD和OPN高表达与BRFS改善相关。
核心结论
- 缺氧与血管生成生物标志物可能预测局部前列腺癌放疗结局及剂量递增获益。
研究设计与样本
- 基于3期随机对照试验的前列腺穿刺活检样本,前瞻性收集行EBRT或EBRT+HDR-BTb患者的组织。
- 采用Cox比例风险模型进行单因素和多因素分析,免疫组化检测HIF1α、GLUT1、OPN及CD-34标记的MVD。
- 主要终点为生化复发无生存(BRFS),次要终点为远处转移无生存(DMFS)。
- 共有204例患者具备免疫组化结果。
主要发现
- OPN升高预测更差BRFS(HR 2.38,95%CI 1.06-5.34,p<0.036)。
- GLUT1升高预测更差BRFS(HR 2.36,95%CI 1.39-4.01,p<0.001)。
- GLUT1升高预测更差DMFS(HR 2.22,95%CI 1.02-4.84,p=0.045)。
- 在EBRT+HDR-BTb组中,MVD升高预测BRFS改善(HR 1.82,95%CI 1.06-3.14,p=0.03)。
- 在EBRT+HDR-BTb组中,OPN升高预测BRFS改善(HR 1.82,95%CI 1.06-3.14,p=0.03),而GLUT1升高预测BRFS改善(HR 0.40,95%CI 0.20-0.79,p=0.009)。
临床怎么用
- 这些生物标志物可能有助于筛选可能从剂量递增(EBRT+HDR-BTb)中获益的患者。
- 需在前瞻性研究(包括缺氧修饰)中进一步验证后方可用于临床决策。
局限性
- 结论需在前瞻性研究(包括缺氧修饰)中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate angiogenic and hypoxia biomarkers to predict outcome in patients receiving external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb) for localised prostate cancer. METHODS: Prostate biopsy samples were collected prospectively in patients entered into a phase 3 randomised controlled trial of patients receiving EBRT or EBRT + HDR-BTb. Univariate and multivariate analyses using Cox proportional hazards model were performed to identify associations between immunohistochemical staining of hypoxia inducible factor 1 alpha (HIF1α), glucose transporter 1 (GLUT1), osteopontin (OPN) and microvessel density (MVD) using CD-34 antibody with clinical outcome. The primary endpoint was biochemical relapse free survival (BRFS) and secondary endpoint was distant metastasis free survival (DMFS). RESULTS: Immunohistochemistry was available for 204 patients. Increased OPN (Hazard ratio [HR] 2.38, 95% Confidence Interval [CI] 1.06-5.34, p < 0.036) and GLUT1 (HR 2.36, 95%CI 1.39-4.01, p < 0.001) expression were predictive of worse BRFS. Increased GLUT1 expression (HR 2.22, 1.02-4.84, p = 0.045) was predictive of worse DMFS. Increased MVD (CD-34) (HR 1.82, 95%CI 1.06-3.14, p = 0.03) and OPN (HR 1.82, 95%CI 1.06-3.14, p = 0.03) but reduced GLUT1 expression (HR 0.40, 95%CI 0.20-0.79, p = 0.009) were predictive of improved BRFS in patients receiving EBRT + HDR-BTb. CONCLUSION: Our data suggest angiogenic and hypoxia biomarkers may predict outcome and benefit of dose escalation, however further validation in prospective studies including hypoxia modification is needed. Trial registration number ISRCTN98241100, registered with ISRCTN at http://www.controlled-trials.com/isrctn/.
引用
- Bhattacharya IS, Taghavi Azar Sharabiani M, Alonzi R, et al. Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). Radiother Oncol. 2019. PMID: 31059955. doi:10.1016/j.radonc.2019.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。